EcoR1 Capital LLC Has $46.45 Million Holdings in Janux Therapeutics, Inc. (NASDAQ:JANX)

EcoR1 Capital LLC increased its holdings in Janux Therapeutics, Inc. (NASDAQ:JANX) by 170.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,838,486 shares of the company’s stock after acquiring an additional 2,417,167 shares during the period. Janux Therapeutics comprises 1.5% of EcoR1 Capital LLC’s investment portfolio, making the stock its 15th biggest holding. EcoR1 Capital LLC owned 9.18% of Janux Therapeutics worth $46,446,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Tower Research Capital LLC TRC raised its holdings in shares of Janux Therapeutics by 149.4% in the 1st quarter. Tower Research Capital LLC TRC now owns 3,344 shares of the company’s stock worth $40,000 after acquiring an additional 2,003 shares during the last quarter. Barclays PLC raised its holdings in shares of Janux Therapeutics by 533.0% in the 4th quarter. Barclays PLC now owns 4,608 shares of the company’s stock worth $61,000 after acquiring an additional 3,880 shares during the last quarter. BNP Paribas Arbitrage SNC acquired a new stake in shares of Janux Therapeutics in the 3rd quarter worth about $103,000. SG Americas Securities LLC acquired a new stake in shares of Janux Therapeutics in the 4th quarter worth about $104,000. Finally, American International Group Inc. raised its holdings in shares of Janux Therapeutics by 25.3% in the 1st quarter. American International Group Inc. now owns 8,813 shares of the company’s stock worth $126,000 after acquiring an additional 1,782 shares during the last quarter. Institutional investors and hedge funds own 75.39% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Wedbush reiterated an “outperform” rating and issued a $24.00 price objective on shares of Janux Therapeutics in a research note on Thursday, August 10th. HC Wainwright reiterated a “buy” rating and issued a $35.00 price objective on shares of Janux Therapeutics in a research note on Wednesday, August 9th.

Insider Transactions at Janux Therapeutics

In related news, Director Ra Capital Management, L.P. purchased 495,008 shares of the firm’s stock in a transaction dated Wednesday, July 19th. The stock was bought at an average price of $12.46 per share, for a total transaction of $6,167,799.68. Following the purchase, the director now directly owns 8,117,246 shares in the company, valued at approximately $101,140,885.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 35.40% of the stock is currently owned by company insiders.

Janux Therapeutics Stock Performance

NASDAQ:JANX opened at $10.30 on Monday. The firm has a market cap of $474.83 million, a price-to-earnings ratio of -6.25 and a beta of 1.57. Janux Therapeutics, Inc. has a 52 week low of $10.10 and a 52 week high of $23.64. The firm has a 50-day moving average price of $12.00 and a two-hundred day moving average price of $12.96.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings results on Tuesday, August 8th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.10. Janux Therapeutics had a negative net margin of 862.89% and a negative return on equity of 21.22%. The company had revenue of $1.06 million during the quarter, compared to analyst estimates of $1.25 million. As a group, sell-side analysts forecast that Janux Therapeutics, Inc. will post -1.81 earnings per share for the current year.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on proprietary Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients suffering from cancer. Its lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2.